This article was originally published in The Gray Sheet
Plans to repurchase up to 1 mil. shares of common stock in the open market. The maker of devices used in the refractive, cataract and glaucoma surgery markets recently rejected a cash offer to have 51-100% of its outstanding common stock acquired by an unnamed party at $15 per share (1"The Gray Sheet" July 5, p. 27). The offer was "inadequate" and "not in the best interest" of shareholders, Staar concluded. Staar stock has recently traded in the $15 range, reaching a 52-week high of 17-1/8. The Monrovia, California firm reported second quarter (ended July 2) revenues of $14.7 mil. (up 5%). Net income was $677,000 versus $1.5 mil. for the comparable quarter last year
You may also be interested in...
Ophthalmic products company is evaluating a cash offer to acquire 51-100% of its outstanding common stock at $15 per share from an unnamed entity "whose principals have not been disclosed," the firm reports in a June 28 release. Monrovia, California-based Staar makes minimally invasive devices for refractive, cataract and glaucoma surgery including foldable intraocular lenses
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.